4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Corvus Pharmaceuticals, Inc. (CRVS) operates in the Biotechnology industry and is headquartered in South San Francisco, United States with about 37 employees. Its market capitalization is roughly $1 billion. In the fiscal year ended 2025-12-31, CRVS reported $0M in revenue and ($15M) in net income.
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($43M) | ($28M) | ($23M) | ($33M) | — |
| Net Income | ($15M) | ($62M) | ($27M) | ($41M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($15M) | ($12M) | ($11M) | ($10M) | ($10M) | — |
| Net Income | ($14M) | ($12M) | ($10M) | ($8M) | $15M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $71M | $69M | $46M | $68M | — |
| Total Liabilities | $10M | $36M | $7M | $12M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CRVS viewer.
About TickerBase · Data methodology & sources